Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥26.84B | ¥23.61B | +13.7% |
| Operating Income | −¥3.48B | ¥1.40B | −348.4% |
| Profit Before Tax | −¥4.65B | ¥0.24B | −2052.1% |
| Net Income | −¥7.32B | −¥0.01B | −81211.1% |
| ROE | −14.2% | −0.0% | - |
Executive Summary
The key point of the full-year results is the shift from revenue growth to a loss, with the expansion in revenue accompanied by deteriorating profitability. Revenue increased to ¥26.84B (+13.7% YoY), while operating income turned from a profit of ¥1.40B in the previous year to an operating loss of ¥3.48B. Net income attributable to owners of the parent was a loss of ¥4.41B, compared with a profit of ¥0.11B in the previous year, primarily due to a sharp increase in SG&A expenses (from ¥15.77B in the previous year to ¥19.00B).
Factors Affecting Earnings
【Revenue】Revenue increased to ¥26.84B (+13.7% YoY). By segment, the Medical Devices Business grew significantly to ¥7.68B (+44.7%), while the Pharmaceuticals Business maintained revenue growth at ¥19.16B (+4.7%). By region, overseas revenue accounted for a high proportion, with China contributing ¥18.50B (68.9% of consolidated revenue) and the United States ¥7.53B. Growth was driven by the expansion of sales to major customer Sinopharm from ¥5.11B to ¥6.74B.
【Profit and Loss】Gross profit remained at a high level of ¥19.99B, with a gross margin of 74.5%; however, SG&A expenses surged to ¥19.00B (70.8%, +20.5% YoY), placing pressure on operating income. Research and development expenses also increased to ¥3.30B from ¥2.81B in the previous year. Segment income for the Pharmaceuticals Business declined from a profit of ¥0.37B in the previous year to a loss of ¥4.01B, driving the deterioration in consolidated operating income. Financial expenses of ¥1.75B also reduced profit before tax, resulting in a loss before tax of ¥4.65B and a net loss attributable to owners of the parent of ¥4.41B. In conclusion, the Company experienced revenue growth but lower earnings, including a shift into the red.
Segment Analysis
The Pharmaceuticals Business generated revenue of ¥19.16B (+4.7% YoY), but segment income turned to a loss of ¥4.01B, compared with a profit of ¥0.37B in the previous year, resulting in a negative margin of 21.0%. The primary factors appear to be increases in research and development expenses and SG&A expenses, making this business the center of the deterioration in consolidated performance. The Medical Devices Business grew significantly, with revenue increasing to ¥7.68B (+44.7%), but operating income decreased to ¥0.53B (-48.6%), and its margin also declined to 6.9%. Despite revenue growth, margins deteriorated in both segments, confirming a cost-front-loaded structure.
Key Financial Indicators
【Profitability】The operating margin deteriorated substantially to -13.0% (previous year: +5.9%), while ROE declined to -10.2% (previous year: +3.1%), and the net profit margin also fell to -27.3%. The gross margin remained high at 74.5%; therefore, the deterioration in profitability was primarily attributable to increases in SG&A expenses and research and development expenses.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥-2.41B, remaining below net loss attributable to owners of the parent (¥-4.41B) in terms of cash generation, while deterioration in working capital (accounts receivable +29.2%, inventories +48.4%) placed pressure on cash flow.【Investment Efficiency】Capital expenditures were restrained at ¥0.33B, while investments in intangible assets of ¥1.22B accounted for the core of investing cash flow. Total asset turnover remained at a low level, and improvements in asset efficiency were limited.【Financial Soundness】The equity ratio increased to 59.9% from 50.7% in the previous year, and the financial base was strengthened through a large-scale capital increase involving the issuance of new shares totaling ¥12.59B. Cash and cash equivalents were ample at ¥21.10B; however, retained earnings decreased to ¥5.48B from ¥9.89B in the previous year (-44.6%), indicating progressive capital impairment due to the recognition of losses.
Cash Flow Analysis
Operating Cash Flow (OCF) was ¥-2.41B, an improvement from ¥-3.16B in the previous year, but it did not sufficiently offset the loss before tax of ¥4.65B. Increases in accounts receivable (¥-1.37B) and inventories (¥-0.99B), together with a decrease in accounts payable (¥-0.91B), placed pressure on working capital, resulting in a negative ¥-1.89B at the subtotal stage. Investing cash flow contracted substantially to ¥-0.54B from ¥-10.36B in the previous year, with expenditures for the acquisition of property, plant and equipment and intangible assets remaining restrained. Financing cash flow was significantly positive at ¥13.74B, primarily reflecting ¥12.59B in funds raised through the issuance of shares. Free cash flow remained negative at ¥-2.94B; however, financing activities increased cash at the end of the period to ¥21.10B from ¥10.12B in the previous year, providing sufficient liquidity for the foreseeable future.
Quality of Earnings
The loss for the current period was primarily attributable to increased expenses at the operating level. Although no specific extraordinary one-time losses, such as impairment losses, were disclosed, other expenses surged to ¥1.70B from ¥0.49B in the previous year, suggesting the possibility of non-recurring factors. Share-based compensation expense expanded sharply to ¥2.21B from ¥0.24B in the previous year. Although this non-cash expense reduced reported earnings, it does not directly affect cash flow, which should be taken into consideration. Operating Cash Flow (OCF) of ¥-2.41B remained above the net loss attributable to owners of the parent of ¥-4.41B, indicating that accrual effects—the divergence between accrual-basis and cash-basis accounting—were limited. Comprehensive income was ¥-6.49B, broadly close to consolidated net loss of ¥-7.32B, with foreign currency translation adjustments of ¥+0.81B partially offsetting the loss.
Shareholder Returns
No dividends were paid for the current period, with dividends per share at ¥0, and the full-year dividend forecast also set at ¥0. The Company recorded a net loss attributable to owners of the parent of ¥4.41B for the current period; accordingly, the payout ratio is not applicable. Free cash flow was also negative at ¥-2.94B, and no improvement in earnings or cash flow sufficient to support the resumption of dividends has been confirmed at this time. There were also no share repurchases, and shareholder returns remain restrained under the current circumstances.
Risk Factors
-
Deterioration in the profitability of the Pharmaceuticals Business: Segment income for the Pharmaceuticals Business declined from a profit of ¥0.37B in the previous year to a loss of ¥4.01B, resulting in a negative margin of 21.0%. This is the primary factor behind the deterioration in consolidated operating income, and trends in the improvement of the cost structure will be a key focus.
-
Deterioration in working capital: Accounts receivable increased to ¥8.06B (+29.2% YoY), inventories increased to ¥3.75B (+48.4%), and accounts payable decreased to ¥1.60B (-29.3%). The accumulation of working capital is placing pressure on Operating Cash Flow (OCF).
-
Customer concentration risk: In the Pharmaceuticals Business, sales to its largest customer, Sinopharm, totaled ¥6.74B, accounting for 25.1% of consolidated revenue, indicating a high degree of dependence on a specific customer.
Industry Benchmark (For Reference; Company Analysis)
Industry Benchmark (pharma)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Return on Equity | −10.2% | 2.1% (1.6%–7.4%) | −12.3pt |
| Operating Margin | −13.0% | 5.0% (3.3%–9.1%) | −18.0pt |
| Net Profit Margin | −27.3% | 3.4% (2.2%–8.0%) | −30.6pt |
All profitability indicators were substantially below the industry median, placing the Company in the bottom tier of the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 13.7% | 5.9% (5.8%–15.6%) | +7.8pt |
The revenue growth rate exceeded the industry median, indicating a relatively favorable pace of revenue growth.
※Source: Company compilation
Key Takeaways from the Financial Results
-
The coexistence of revenue growth and deteriorating profitability is the structural feature of the full-year results. While revenue growth exceeded the industry median, the operating margin and ROE ranked in the lower tier of the industry. The figures confirm that the growth in SG&A expenses and research and development expenses exceeded revenue growth.
-
The segment loss in the Pharmaceuticals Business of ¥4.01B was the central factor behind the deterioration in consolidated performance, and the profitability gap with the Medical Devices Business, which had a margin of 6.9%, widened. Profitability trends by business will be a key point to monitor in future results.
-
From a financial perspective, the equity ratio increased to 59.9% through the large-scale capital increase, and cash and cash equivalents accumulated to ¥21.10B. Meanwhile, retained earnings decreased by 44.6% from the previous year, indicating that changes in the capital structure and the impact of recognized losses are progressing in parallel.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.
---End of Report---